CUTIA-B (02487) announced its 2025 interim results, with revenue decreasing 30.6% year-over-year to approximately 66.3 million yuan, and gross profit of approximately 32.1 million yuan, down 36.3% year-over-year. The company reported a net loss of approximately 239 million yuan, representing an increase of about 19.1% compared to the same period last year. Loss per share was 0.75 yuan.

According to the announcement, the revenue decrease was primarily due to the group's prudent decision to terminate its agency cooperation with US skincare brand under the influence of macro policies and international environment. The company has reallocated resources toward the commercialization preparation of new products that have received regulatory approval, including CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam). These new products are expected to have greater market potential and higher return on investment, and the adjustment is anticipated to benefit the group's medium to long-term development.